Mumbai: Metropolis Healthcare Limited announced the launch of a new testing platform based on Resolved Component Diagnostics (CRD) to support the people of India in the diagnosis of various forms of allergies. Fourth generation allergy testing technology uses artificial intelligence (AI) to help clinicians make sound clinical decisions and provides great insight in selecting and optimizing the course of treatment regarding an individual’s allergic disease.
Powered by a nanotechnology-based Multiplex system using molecular components, the test can easily detect specific IgE antibodies against 295 different allergens using a simple blood test and provides results for 158 food allergens, 127 respiratory allergens, and 10 contact allergens. For example, if a patient is allergic to milk, you can predict whether a patient can probably consume boiled or baked milk without danger of clinical reactions, or whether they need to avoid milk in all forms altogether. You can also predict if immunotherapycommonly known as allergy shots, will be effective or not.
Through this molecular component-based allergy diagnostic test, a patient’s allergen sensitization can be mapped at the protein level, allowing for better identification and characterization of the specific molecules that trigger allergic reactions. Knowledge of the allergenic molecules to which the patient is sensitized can help to distinguish between the probability of local and systemic reactions and the persistence of clinical symptoms.
Commenting on the launch of the trial, Surendran Chemmenkotil, CEO, Metropolis Healthcare Ltd, said: “The arrival of CRD represents a milestone in the field of allergy diagnostics and will help clinicians chart a precise course of treatment for their patients. The launch of this test is also in line with the company’s goal to offer and novel tests for patients and clients in the chronic and wellness segments”.
Sharing his thoughts on the need for such tests, Dr Nilesh Shah, Chairman and Head of Science and Innovation at Metropolis Healthcare Ltd, said: “The most important clinical use of Metropolis Allergy component tests is their ability to identify the offending allergen molecule and to distinguish specific cross-reactive marker molecules.This knowledge will greatly benefit physicians, patients, and nutritionists, as it ensures better correlation with clinical symptoms, thus aiding in the proper selection of patients for immunotherapy. This will improve immunotherapeutic success by minimizing adverse reactions in patients receiving immunotherapy. We are excited to witness the impact this would have on the Indian healthcare system and look forward to launching many more novel solutions for a healthier India.” and through home collection services throughout the country.
